New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTSPPI, LGNDSpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticals’ (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
16:07 EDTLGNDLigand sees FY16 adjusted EPS $3.37-$3.42, consensus $3.41
Subscribe for More Information
16:02 EDTLGNDLigand reports Q4 EPS 66c, consensus 65c
Subscribe for More Information
February 2, 2016
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.
January 29, 2016
07:04 EDTSPPISpectrum begins enrolling patients in registrational SPI-2012 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use